Background: The diagnosis of neurodegenerative diseases such as dementia due to Alzheimer's Disease (AD) and other dementias continues to be a challenge. The use of complementary studies in diagnosis is recommended in the main clinical guidelines for this pathology. Biomarkers in CSF (Aβ42, tTau and pTau) and by brain [18F]FDG-PET are useful for diagnosis, since they increase its certainty.
Objective: Establish diagnostic agreement between biomarkers in CSF, PET and clinical evaluation.
Method: Cohort, retrospective and comparative study. Patients with biomarkers were included for the diagnostic approach of cognitive impairment due to any cause in the INCMNSZ from July 2018 to September 2023. An analysis of concordance was carried out with the Kappa coefficient between the result of the biomarkers and the clinical assessment.
Result: 77 patients were evaluated, with an average age of 71 years (SD ± 10.19) and 53.2% were men; 27.3% with a diagnosis of mild cognitive impairment (MCI) and 72.7% with dementia. The agreement between the initial diagnosis and the hypometabolism patterns by PET was moderate (kappa 0.461, p=0.011). The overall agreement between the biomarkers to differentiate between AD and other dementias was 88% (kappa 0.694, p=0.002). The change in diagnosis after taking the biomarkers occurred in 46% of the patients.
Conclusion: This study demonstrates that the agreement between the use of CSF and PET biomarkers to differentiate between AD and other dementias is good. There was disagreement in 12% of the patients, which suggests that in cases with diagnostic doubt it is advisable to perform both biomarkers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.088290 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eating Pathology and Interoceptive Sensibility Using the Brief Multidimensional Assessment of Interoceptive Awareness-2: Can There be Too Much of a Good Thing?
J Pers Assess
January 2025
Department of Clinical and School Psychology, Nova Southeastern University.
This study evaluated the factorial structure and invariance of the Multidimensional Assessment of Interoceptive Awareness-v2 (MAIA-2). We also investigated incremental validity of the MAIA-2 factors for predicting eating pathology beyond appetite-based interoception. US-based online respondents ( = 1294; =48.
View Article and Find Full Text PDFMir-615-5p inhibits cervical cancer progression by targeting TMIGD2.
Hereditas
January 2025
Obstetrics and Gynecology Medical Centre, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, No.105, Shaoshan Middle Road, Yuhua District, Changsha, 410007, Hunan, China.
Background: Cervical cancer (CC) is a prevalent gynecological malignancy, contributing to a substantial number of fatalities among women. MicroRNAs (miRNAs) have emerged as promising biomarkers with significant potential for the early detection and prognosis of CC.
Objective: This study aimed to explore the clinical significance and biological role of miR-615-5p in CC, with the goal of identifying novel biomarkers for this disease.
Faricimab efficacy in type 1 macular neovascularization: AI-assisted quantification of pigment epithelium detachment (PED) volume reduction over 12 months in Naïve and switch eyes.
Int J Retina Vitreous
January 2025
Fondation Asile des Aveugles, Department of Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Avenue de France 54, Lausanne, 1001, Switzerland.
Background: This study evaluates the efficacy of intravitreal Faricimab in reducing pigment epithelium detachment (PED) and fluid volumes in both treatment-naïve eyes and eyes unresponsive to anti-VEGF mono-therapies, all diagnosed with type 1 macular neovascularization (T1 MNV) over a period of 12-month.
Methods: A retrospective, single-center cohort study was conducted at the Jules Gonin Eye Hospital, Lausanne, Switzerland. Clinical records of treatment-naïve and non-responder switch patients presenting T1 MNV secondary to neovascular age-related macular degeneration (nAMD) from September 2022 to March 2023 were reviewed.
Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.
Fluids Barriers CNS
January 2025
Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, 760 Press Ave, 124 HKRB, Lexington, KY, 40536-0679, USA.
Background: Blood-brain barrier dysfunction is one characteristic of Alzheimer's disease (AD) and is recognized as both a cause and consequence of the pathological cascade leading to cognitive decline. The goal of this study was to assess markers for barrier dysfunction in postmortem tissue samples from research participants who were either cognitively normal individuals (CNI) or diagnosed with AD at the time of autopsy and determine to what extent these markers are associated with AD neuropathologic changes (ADNC) and cognitive impairment.
Methods: We used postmortem brain tissue and plasma samples from 19 participants: 9 CNI and 10 AD dementia patients who had come to autopsy from the University of Kentucky AD Research Center (UK-ADRC) community-based cohort; all cases with dementia had confirmed severe ADNC.
OSBPL3 modulates the immunosuppressive microenvironment and predicts therapeutic outcomes in pancreatic cancer.
Biol Direct
January 2025
School of Medicine, South China University of Technology, Guangzhou, 510006, China.
Background: Pancreatic cancer is characterized by a complex tumor microenvironment that hinders effective immunotherapy. Identifying key factors that regulate the immunosuppressive landscape is crucial for improving treatment strategies.
Methods: We constructed a prognostic and risk assessment model for pancreatic cancer using 101 machine learning algorithms, identifying OSBPL3 as a key gene associated with disease progression and prognosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!